Niraparib - Wikipedia
WEBNiraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
Niraparib Uses, Side Effects & Warnings - Drugs.com
WEBWhat is niraparib? Niraparib is used as a "maintenance" treatment in adults to keep certain types of cancer from coming back. This includes cancers of the ovary, fallopian tube, or peritoneum (the membrane that lines the inside of your abdomen and covers some of your internal organs).
FDA approves niraparib for first-line maintenance of advanced …
WEBOn April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube,...
Niraparib in Patients with Newly Diagnosed Advanced Ovarian …
WEBSep 28, 2019 · Niraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent...
niraparib oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
WEBGeneric Name: niraparib. Niraparib is used to treat ovarian cancer, fallopian tube cancer, or a type of cancer of the abdomen (primary peritoneal cancer ). It works by slowing the growth of...
Niraparib (ZEJULA) | FDA
WEBOn March 27, 2017 , the U.S. Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients...
Niraparib (Oral Route) Description and Brand Names - Mayo …
WEBNiraparib is used as first-line maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Niraparib maintenance therapy using an individualised starting …
WEBMay 7, 2024 · Niraparib maintenance therapy with an individualised starting dose demonstrated a favourable OS trend versus placebo in PSROC patients, regardless of gBRCAm status.
Niraparib Advanced Patient Information - Drugs.com
WEBJan 25, 2024 · Niraparib is used as first-line maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism …
WEBAug 7, 2021 · Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor. It is approved as a maintenance treatment for epithelial ovarian cancer which has demonstrated response to platinum chemotherapy.
- Some results have been removed